PMID- 20205668
OWN - NLM
STAT- MEDLINE
DCOM- 20100609
LR  - 20191027
IS  - 1875-5828 (Electronic)
IS  - 1567-2050 (Linking)
VI  - 7
IP  - 1
DP  - 2010 Feb
TI  - Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) patients are 
      characterized by increased BDNF serum levels.
PG  - 15-20
AB  - Alzheimer's disease (AD) is a neurodegenerative disorder characterized by 
      cognitive decline with loss of memory. In the last years there has been a great 
      interest on the early phases of AD, trying to identify the pathogenic mechanisms 
      of AD and define early treatment modalities. In particular, Mild Cognitive 
      Impairment (MCI) is attractive because it represents a transitional state between 
      normal aging and dementia, although not all MCI patients automatically convert to 
      AD. The neurotrophin brain-derived neurotrophic factor (BDNF) is critical for 
      survival and function of neurons that degenerate in AD and represents a potential 
      neuroprotective agent. However, opposite data on serum levels of BDNF have been 
      reported in AD patients, probably reflecting differences in patient recruitment 
      and stage of the disease. Thus, in this study we measured BDNF serum levels in AD 
      patients (with different degree of severity), MCI patients and healthy subjects. 
      We found that serum BNDF levels were significantly increased in MCI and AD 
      patients when compared to healthy subjects and this increase in AD patients was 
      neither dependent on illness severity, nor on treatment with Acetylcholinesterase 
      inhibitors and/or antidepressant medications. Our findings indicate that BDNF 
      serum levels increase in MCI and AD patients, supporting the hypothesis of an 
      upregulation of BDNF in both preclinical phase of dementia (MCI) and clinical 
      stages of AD. Other studies are necessary to establish a direct link between BDNF 
      peripheral levels and AD longitudinal course, as well as the role of other 
      factors, such as blood cell activation, in determining these events.
FAU - Angelucci, Francesco
AU  - Angelucci F
AD  - Department of Clinical and Behavioural Neurology, 00179, Rome, Italy. 
      f.angelucci@hsantalucia.it
FAU - Spalletta, Gianfranco
AU  - Spalletta G
FAU - di Iulio, Fulvia
AU  - di Iulio F
FAU - Ciaramella, Antonio
AU  - Ciaramella A
FAU - Salani, Francesca
AU  - Salani F
FAU - Colantoni, Luca
AU  - Colantoni L
FAU - Varsi, Ambra Erika
AU  - Varsi AE
FAU - Gianni, Walter
AU  - Gianni W
FAU - Sancesario, Giuseppe
AU  - Sancesario G
FAU - Caltagirone, Carlo
AU  - Caltagirone C
FAU - Bossu, Paola
AU  - Bossu P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Alzheimer Res
JT  - Current Alzheimer research
JID - 101208441
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/*blood
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cognition Disorders/*blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Male
MH  - Neuropsychological Tests
EDAT- 2010/03/09 06:00
MHDA- 2010/06/10 06:00
CRDT- 2010/03/09 06:00
PHST- 2008/12/29 00:00 [received]
PHST- 2009/02/20 00:00 [accepted]
PHST- 2010/03/09 06:00 [entrez]
PHST- 2010/03/09 06:00 [pubmed]
PHST- 2010/06/10 06:00 [medline]
AID - CAR-17 [pii]
AID - 10.2174/156720510790274473 [doi]
PST - ppublish
SO  - Curr Alzheimer Res. 2010 Feb;7(1):15-20. doi: 10.2174/156720510790274473.